

In the Claims

Claim 1 (Currently amended): A method for treating a neurological condition, said method comprising co-administering metanicotine, or a pharmaceutically acceptable salt thereof, and at least one compound selected from the group consisting of ~~acetylcholine~~; nicotine; 3-[2,4-dimethoxybenzylidene]-anabaseine (GTS-21); 2-methyl-3-(2-(S)-pyrrolidinyl methoxy)pyridine (ABT-089); (S)-3-methyl-S-(1-methyl-2-pyrrolidinyl)isoxazole (ABT-418); (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594); altinicline (SIB-1508Y); (\pm)-4-{{2-(1-methyl-2-pyrrolidinyl)ethyl}thio}phenol hydrochloride (SIB-1553A); epibatadine; and mecamlamine; or a pharmaceutically acceptable salt of any of the foregoing, to a patient in need of such treatment, wherein the neurological condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's chorea, tardive dyskinesia, hyperkinesias, mania, attention deficit disorder, attention deficit hyperactivity disorder, sleep-wake disorder, chronic-fatigue syndrome, tremor, epilepsy, neuropathic pain, addiction, anxiety, dyslexia, schizophrenia, obsessive-compulsive disorder and Tourette's syndrome, or combinations of any of the foregoing.

Claim 2 (Cancelled)

Claim 3 (Previously amended): The method, according to claim 1, wherein the metanicotine, or pharmaceutically acceptable salt thereof, and the compound are administered to the patient consecutively.

Claim 4 (Previously amended): The method, according to claim 1, wherein the metanicotine, or pharmaceutically acceptable salt thereof, and the compound are administered to the patient simultaneously.

Claim 5 (Previously amended): The method, according to claim 1, wherein the metanicotine, or pharmaceutically acceptable salt thereof, and the compound are administered to the patient simultaneously and in the form of a pharmaceutical composition.

Claim 6 (Cancelled)

Claim 7 (Original): The method, according to claim 1, wherein the patient is suffering from the neurological condition.

Claim 8 (Original): The method, according to claim 1, wherein the route of administration is selected from the group consisting of intravenous, oral, and intra-nasal.

Claim 9 (Previously amended): The method, according to claim 1, wherein the metanicotine, or pharmaceutically acceptable salt thereof, and the compound administered to the patient do not cause an adverse side effect in the patient which is normally associated with administration of the compound alone, or wherein the metanicotine, or pharmaceutically acceptable salt thereof, and the compound administered to the patient cause an adverse side effect in the patient which is normally associated with administration of the compound alone, but of decreased intensity.

Claim 10 (Previously amended): The method, according to claim 1, wherein the metanicotine, or pharmaceutically acceptable salt thereof, and the compound are administered in amounts sufficient to penetrate the blood-brain barrier.

Claims 11-20 (Cancelled)